| Guidelines for the diagnosis and management of adult aplastic anaemia. SB Killick, N Bown, J Cavenagh, I Dokal, T Foukaneli, A Hill, P Hillmen, ... British journal of haematology 172 (2), 2016 | 752 | 2016 |
| TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression M Jädersten, L Saft, A Smith, A Kulasekararaj, S Pomplun, G Göhring, ... Journal of clinical oncology 29 (15), 1971-1979, 2011 | 562 | 2011 |
| TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis AG Kulasekararaj, AE Smith, SA Mian, AM Mohamedali, P Krishnamurthy, ... British journal of haematology 160 (5), 660-672, 2013 | 317 | 2013 |
| Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study AG Kulasekararaj, A Hill, ST Rottinghaus, S Langemeijer, R Wells, ... Blood, The Journal of the American Society of Hematology 133 (6), 540-549, 2019 | 312 | 2019 |
| Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite … AE Smith, AM Mohamedali, A Kulasekararaj, ZY Lim, J Gäken, NC Lea, ... Blood, The Journal of the American Society of Hematology 116 (19), 3923-3932, 2010 | 298 | 2010 |
| Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome AG Kulasekararaj, J Jiang, AE Smith, AM Mohamedali, S Mian, S Gandhi, ... Blood, The Journal of the American Society of Hematology 124 (17), 2698-2704, 2014 | 266 | 2014 |
| COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) L Pagano, J Salmanton-García, F Marchesi, A Busca, P Corradini, ... Journal of hematology & oncology 14 (1), 168, 2021 | 250 | 2021 |
| Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies RV Tiu, LP Gondek, CL O'Keefe, P Elson, J Huh, A Mohamedali, ... Blood, The Journal of the American Society of Hematology 117 (17), 4552-4560, 2011 | 237 | 2011 |
| Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria RJ Kelly, B Höchsmann, J Szer, A Kulasekararaj, S De Guibert, A Röth, ... New England Journal of Medicine 373 (11), 1032-1039, 2015 | 236 | 2015 |
| Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes DA Sallman, R Komrokji, C Vaupel, T Cluzeau, SM Geyer, KL McGraw, ... Leukemia 30 (3), 666-673, 2016 | 217 | 2016 |
| Functional characterization of CD4+ T cells in aplastic anemia S Kordasti, J Marsh, S Al-Khan, J Jiang, A Smith, A Mohamedali, ... Blood, The Journal of the American Society of Hematology 119 (9), 2033-2043, 2012 | 214 | 2012 |
| Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 … EN Oliva, C Alati, V Santini, A Poloni, A Molteni, P Niscola, F Salvi, ... The Lancet Haematology 4 (3), e127-e136, 2017 | 180 | 2017 |
| Similar outcome of upfront‐unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working … C Dufour, P Veys, E Carraro, N Bhatnagar, M Pillon, R Wynn, B Gibson, ... British journal of haematology 171 (4), 585-594, 2015 | 178 | 2015 |
| Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT AM Risitano, S Marotta, P Ricci, L Marano, C Frieri, F Cacace, M Sica, ... Frontiers in immunology 10, 1157, 2019 | 174 | 2019 |
| STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients A Jerez, MJ Clemente, H Makishima, H Rajala, I Gómez-Seguí, T Olson, ... Blood, The Journal of the American Society of Hematology 122 (14), 2453-2459, 2013 | 169 | 2013 |
| p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del (5q) L Saft, M Karimi, M Ghaderi, A Matolcsy, GJ Mufti, A Kulasekararaj, ... haematologica 99 (6), 1041, 2014 | 167 | 2014 |
| Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis A Jerez, Y Sugimoto, H Makishima, A Verma, AM Jankowska, ... Blood, The Journal of the American Society of Hematology 119 (25), 6109-6117, 2012 | 142 | 2012 |
| Eltrombopag added to immunosuppression in severe aplastic anemia R Peffault de Latour, A Kulasekararaj, S Iacobelli, SR Terwel, R Cook, ... New England Journal of Medicine 386 (1), 11-23, 2022 | 139 | 2022 |
| Autoimmune diseases and myelodysplastic syndromes RS Komrokji, A Kulasekararaj, NH Al Ali, S Kordasti, E Bart‐Smith, ... American journal of hematology 91 (5), E280-E283, 2016 | 139 | 2016 |
| Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment S Kordasti, B Costantini, T Seidl, P Perez Abellan, M Martinez Llordella, ... Blood, The Journal of the American Society of Hematology 128 (9), 1193-1205, 2016 | 138 | 2016 |
judith marshVerified email at kcl.ac.uk
